Compare AbbVie Inc (ABBV) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? AbbVie Inc trades at $251 (market cap $441.94B), while State Street SPDR S&P Homebuilders ETF trades at $108.36. The key difference: AbbVie Inc pays a 2.77% dividend while State Street SPDR S&P Homebuilders ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XHB | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $121.36 |
52-Week Low | $197.38 | $94.86 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.94, up 0.82% today, with bullish technical signals and strong analyst support. Recent earnings beats, including Q2 2026 EPS of $3.65 versus $3.61 expected, highlight robust immunology growth from Skyrizi and Rinvoq offsetting Humira declines. Positive Phase 2 data for ELAHERE in ovarian cancer (SGO 2026, April 12) and a $1.73 dividend reinforce momentum, though high P/E of 70.65 and debt levels warrant caution.
Outlook remains positive with a consensus price target of $278.69, driven by pipeline innovation and earnings resilience. Risks include patent expirations in the 2030s and regulatory pressures, but institutional buying and a 70.73% buy rating suggest confidence in sustained growth amid sector volatility.
XHB trades at $108.35 with a slight 0.1% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overall bullish sentiment with 14 buy signals versus 3 sell signals.
The outlook remains cautiously optimistic as housing affordability legislation and seasonal demand provide tailwinds, but high mortgage rates and record home prices pose headwinds. Key risks include interest rate sensitivity and economic volatility, while institutional positioning suggests selective confidence in the homebuilding sector's recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
